Melanoma

**IRB#11848**
Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

**IRB#15661**
A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

**IRB#16125**
A Phase 1b/2, Open-label, Dose-escalation and Expansion Trial of Tumor Injections of SD-101 with Pembrolizumab in Patients With Metastatic Melanoma

**IRB#16198**
A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides Compared to IMCgp100 Alone

**IRB#16225**
A Phase Ib/II Open-label Study of IMCgp100 + Durvalumab or Tremelimumab + Durvalumab Compared to IMCgp100 Alone

**IRB#15298**
Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With BRAFV600 Mutant Melanoma

**IRB#16162**
A Phase 1, Open-label, Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

**IRB#111848**
Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

**IRB#15661**
A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

**IRB#16125**
A Phase 1b/2, Open-label, Dose-escalation and Expansion Trial of Tumor Injections of SD-101 with Pembrolizumab in Patients With Metastatic Melanoma

**IRB#16198**
A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides Compared to IMCgp100 Alone

**IRB#16225**
A Phase Ib/II Open-label Study of IMCgp100 + Durvalumab or Tremelimumab + Durvalumab Compared to IMCgp100 Alone

**IRB#15298**
Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With BRAFV600 Mutant Melanoma

**Non-Mutation Specific**

**Mutation Specific**

**BRAF V600 Mutation**

**Stages 3 or 4, unresectable**

**Adjuvant Therapies**

**Uveal Melanoma**

**Please refer to Phase I studies for more clinical trial opportunities**

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php